Cargando…

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who recei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, Yakoub-Agha, Ibrahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632691/ https://www.ncbi.nlm.nih.gov/pubmed/34023851 http://dx.doi.org/10.1038/s41375-021-01276-4

Ejemplares similares

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
por: Drozd-Sokołowska, Joanna, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
por: Chalandon, Yves, et al.
Publicado: (2022)

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
por: Cremers, E. M. P., et al.
Publicado: (2016)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
por: Robin, Marie, et al.
Publicado: (2023)

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
por: Passweg, Jakob R., et al.
Publicado: (2023)

Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy
por: Yakoub-Agha, Ibrahim, et al.
Publicado: (2023)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2020)

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
por: Pavlů, Jiří, et al.
Publicado: (2019)

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2021)

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
por: Tournilhac, Olivier, et al.
Publicado: (2023)

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
por: Passweg, Jakob R., et al.
Publicado: (2020)

Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies
por: Langabeer, Stephen E., et al.
Publicado: (2014)

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
por: Passweg, Jakob R., et al.
Publicado: (2021)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis
por: Langabeer, Stephen E., et al.
Publicado: (2018)

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?
por: McLornan, Donal, et al.
Publicado: (2013)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
por: Passweg, Jakob R., et al.
Publicado: (2019)

Intravesical recurrence of chromophobe renal cell carcinoma
por: Kelly, Niall P., et al.
Publicado: (2023)

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2021)

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
por: Raj, Kavita, et al.
Publicado: (2022)

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Saccardi, Riccardo, et al.
Publicado: (2023)

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
por: Gilleece, Maria H., et al.
Publicado: (2021)

Physicians Abstracts: EBMT 2010
Publicado: (2010)

Publication only: EBMT 2010
Publicado: (2010)

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
por: Passweg, Jakob R., et al.
Publicado: (2022)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Snowden, John A., et al.
Publicado: (2019)

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Yakoub-Agha, Ibrahim, et al.
Publicado: (2020)

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Snowden, John A., et al.
Publicado: (2019)

Urosepsis and the urologist!
por: Ryan, James, et al.
Publicado: (2021)

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia
por: Lierman, Els, et al.
Publicado: (2019)

Physicians Poster Abstracts: EBMT 2012
Publicado: (2012)

Physicians Poster Abstracts: EBMT 2010
Publicado: (2010)

Physicians Oral Abstracts: EBMT 2012
Publicado: (2012)

Physicians Poster Abstracts: EBMT 2011
Publicado: (2011)

47th Annual Meeting of the EBMT
por: del Pozo Martín, Yaiza
Publicado: (2021)

The coming of age of the pediatric EBMT criteria
por: Corbacioglu, Selim
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2mk935nmo6lfhqlunsn918p23b